Eiji Shinozaki

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 274 citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +9

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki et al. · The Lancet Oncology · 2017 · 171 citations

Phase 1/2, Gastrointestinal Oncology, Medicine +6

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer

Satoshi Matsusaka, Keisho Chìn, Mariko Ogura et al. · Cancer Science · 2010 · 121 citations · Full text

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

Nozomu Fuse, Yasutoshi Kuboki, Takeshi Kuwata et al. · Gastric Cancer · 2015 · 112 citations · Full text

Prognostic Impact, Esophageal Cancer, Overall Survival +9

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

Takeru Wakatsuki, Noriko Yamamoto, Takeshi Sano et al. · Journal of Gastroenterology · 2018 · 100 citations · Full text